Fluoropharma Medical Inc (FPMI) financial statements (2020 and earlier)

Company profile

Business Address 8 HILLSIDE AVENUE
MONTCLAIR, NJ 07042
State of Incorp. NV
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments252912921,1431,304
Cash and cash equivalents252912521,1431,304
Short-term investments  40  
Receivables52332754  
Prepaid expense23354159 
Deferred costs  64  
Prepaid expense and other current assets5377
Other undisclosed current assets(523)(327)(117)635 
Total current assets:486454511,8311,381
Noncurrent Assets
Property, plant and equipment7111235177
Intangible assets, net (including goodwill)2803193584955
Intangible assets, net (excluding goodwill)2803193584955
Deferred costs  104  
Other undisclosed noncurrent assets  (104)  
Total noncurrent assets:28733036985232
TOTAL ASSETS:3359758201,9161,614
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,0292,8442,139423236
Accounts payable1,4141,2201,064183138
Accrued liabilities2,6151,6041,07524098
Interest and dividends payable 21   
Debt6,0004,4862,123  
Other undisclosed current liabilities4841,5051,3542,549 
Total current liabilities:10,5148,8355,6172,972236
Noncurrent Liabilities
Total liabilities:10,5148,8355,6172,972236
Stockholders' equity
Stockholders' equity attributable to parent, including:(10,179)(7,860)(4,797)(1,056)1,378
Preferred stock00122
Common stock3433292624
Additional paid in capital24,95924,70624,03423,08418,242
Accumulated deficit(35,178)(32,604)(28,867)(24,175)(16,891)
Warrants and rights outstanding  1,3542,549 
Other undisclosed stockholders' equity attributable to parent55(1,349)(2,543) 
Total stockholders' equity:(10,179)(7,860)(4,797)(1,056)1,378
TOTAL LIABILITIES AND EQUITY:3359758201,9161,614

Income statement (P&L) ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues2716   
Financial services revenue 716   
Other income2 
Cost of revenue
(Cost of Goods and Services Sold)
(250) (175)  
Gross profit:(248)716(175)  
Operating expenses(2,202)(3,186)(5,169)(4,362)(4,150)
Other undisclosed operating income248    
Operating loss:(2,202)(2,470)(5,344)(4,362)(4,150)
Nonoperating income (expense)153231,038(1,245)133
Interest and debt expense(996)(873)(104)(51) 
Other undisclosed income from continuing operations before equity method investments, income taxes 15727951 
Loss before gain (loss) on sale of properties:(3,046)(3,164)(4,131)(5,607)(4,017)
Other undisclosed net income (loss)472(574)(562)(1,677)(168)
Net loss:(2,573)(3,738)(4,692)(7,284)(4,185)
Other undisclosed net income attributable to parent5235745621,677168
Net loss attributable to parent:(2,050)(3,164)(4,131)(5,607)(4,017)
Preferred stock dividends and other adjustments   1,677168
Net loss available to common stockholders, diluted:(2,050)(3,164)(4,131)(3,931)(3,849)

Comprehensive Income ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(2,573)(3,738)(4,692)(7,284)(4,185)
Comprehensive loss, net of tax, attributable to parent:(2,573)(3,738)(4,692)(7,284)(4,185)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: